The NetworkNewsAudio Interviews Podcast: Recent Episodes
networknewsaudiointerviews
ev Transportation Services (“evTS”) is a specialty vehicle OEM that produces purpose built, all-electric lightweight commercial utility vehicles and fleet management solutions. The Boston-based company is currently focused on the essential services transportation and urban mobility markets, which represent an annual domestic replacement market of approximately 100,000 vehicles, or roughly $2.5 billion annually. End-user applications for the company’s vehicles include, among others, parking enforcement, security patrol, utility meter reading, property and building management, sanitation, airports, seaports, university and corporate campuses, warehouses and fulfilment, and last mile on-demand urban delivery. For more information, visit the company’s website at www.evTS.com.
ev Transportation Services (“evTS”) is a specialty vehicle OEM that produces purpose built, all-electric lightweight commercial utility vehicles and fleet management solutions. The Boston-based company is currently focused on the essential services transportation and urban mobility markets, which represent an annual domestic replacement market of approximately 100,000 vehicles, or roughly $2.5 billion annually. End-user applications for the company’s vehicles include, among others, parking enforcement, security patrol, utility meter reading, property and building management, sanitation, airports, seaports, university and corporate campuses, warehouses and fulfilment, and last mile on-demand urban delivery. For more information, visit the company’s website at www.evTS.com.
Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.”
Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.”
LOS ANGELES (December 16, 2020) – via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), recently appeared on the Want Money Got Money Podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world’s most brilliant and interesting startup founders and investors.
The podcast, hosted by Author, Founder, Speaker and CEO Sam Kamani, is available for on-demand listening at https://samkamani.buzzsprout.com. During the interview, Climaco discussed the research of CNS Pharmaceuticals founder Dr. Waldemar Priebe into the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. He also provided an overview of the company’s lead drug candidate, Berubicin, which is proposed for the treatment of GBM. Berubicin has been evaluated in a Phase I clinical trial, where 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS has applied to the U.S. Food and Drug Administration to begin a Phase II clinical trial and expects to begin enrolling patients in this trial in the first quarter of 2021.
LOS ANGELES (December 16, 2020) – via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), recently appeared on the Want Money Got Money Podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world’s most brilliant and interesting startup founders and investors.
The podcast, hosted by Author, Founder, Speaker and CEO Sam Kamani, is available for on-demand listening at https://samkamani.buzzsprout.com. During the interview, Climaco discussed the research of CNS Pharmaceuticals founder Dr. Waldemar Priebe into the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. He also provided an overview of the company’s lead drug candidate, Berubicin, which is proposed for the treatment of GBM. Berubicin has been evaluated in a Phase I clinical trial, where 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS has applied to the U.S. Food and Drug Administration to begin a Phase II clinical trial and expects to begin enrolling patients in this trial in the first quarter of 2021.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I’ve done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn’t seen a lot of hope for a very long time in glioblastoma.”
To view the full press release, visit https://nnw.fm/jfjZB
CNS Pharmaceuticals (NASDAQ: CNSP) is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I’ve done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn’t seen a lot of hope for a very long time in glioblastoma.”
To view the full press release, visit https://nnw.fm/jfjZB
CNS Pharmaceuticals (NASDAQ: CNSP) is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.
Pac Roots (CSE: PACR) is focused on delivering the finest genetics to Canadians. Preserving the excellence of its elite strains while introducing the highest quality of new strains to the public is the company’s passion. The foundation, based on genetic variation and stability, drives the decision making for Pac Roots Cannabis Corp.’s business.
Gage Cannabis is a premium adult-use cannabis retailer in Ayer, Massachusetts with a mission to provide customers with a diverse selection of the best cannabis and cannabis-infused products available in Massachusetts.
For more information, visit the company’s website at www.GageCannabisCo.com.
Pac Roots (CSE: PACR) is focused on delivering the finest genetics to Canadians. Preserving the excellence of its elite strains while introducing the highest quality of new strains to the public is the company’s passion. The foundation, based on genetic variation and stability, drives the decision making for Pac Roots Cannabis Corp.’s business.
Gage Cannabis is a premium adult-use cannabis retailer in Ayer, Massachusetts with a mission to provide customers with a diverse selection of the best cannabis and cannabis-infused products available in Massachusetts.
For more information, visit the company’s website at www.GageCannabisCo.com.
GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF) is a Canadian junior exploration company active in the Maricunga Gold Belt of Northern Chile. The Maricunga measures 150 km north-south and 30 km. east-west and is host to discoveries in the last 10 years of 100M oz. gold; 450M oz. silver and 1.3 billion lbs. copper. The company has agreements in place to acquire seven projects with extensive surface study. GoldHaven has identified four of its seven properties as “high-priority targets,” three of which the company plans to drill commencing January 2021. These priority targets were designated as such due, first, to the analytical work that has been completed on all the properties and, second, to their relative locations in respect to existing deposits. One such existing project is Coya, located approximately 16 km. northeast of the La Coipa mine, where Kinross extracted over 6.2 million oz. Other existing projects include Rio Loa and Alicia, which are respectively 25 km. and 30 km. distance from GoldHaven’s Salares Norte deposit with a discovery of 5M oz. gold, 450M oz. silver and 1.3B lbs. copper.
GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF) is a Canadian junior exploration company active in the Maricunga Gold Belt of Northern Chile. The Maricunga measures 150 km north-south and 30 km. east-west and is host to discoveries in the last 10 years of 100M oz. gold; 450M oz. silver and 1.3 billion lbs. copper. The company has agreements in place to acquire seven projects with extensive surface study. GoldHaven has identified four of its seven properties as “high-priority targets,” three of which the company plans to drill commencing January 2021. These priority targets were designated as such due, first, to the analytical work that has been completed on all the properties and, second, to their relative locations in respect to existing deposits. One such existing project is Coya, located approximately 16 km. northeast of the La Coipa mine, where Kinross extracted over 6.2 million oz. Other existing projects include Rio Loa and Alicia, which are respectively 25 km. and 30 km. distance from GoldHaven’s Salares Norte deposit with a discovery of 5M oz. gold, 450M oz. silver and 1.3B lbs. copper.
Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.
Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.
After offering some brief insight into the operations of Skyline Medical, Schwartz turned his attention toward TumorGenesis. “TumorGenesis is an interesting company. The whole purpose of it was to develop a lab media to replace rats and mice in the scientific industries and in the testing of tumors,” he stated in the interview. “They have developed the first one, which is ovarian cancer, and the results of this are that this media, which, as I said, replicates the body, fools the tumor into thinking it’s still in the body. Its reactions are very, very similar to what it would have done had it been in the body. Now, the next step is to get it positioned to manufacturers and getting the kits out so people can use it. That’s coming along handsomely. It’ll take a little time to get all this put in place, but the optimism is there, and the results are wonderful. We’re very excited.”
Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.
Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.
After offering some brief insight into the operations of Skyline Medical, Schwartz turned his attention toward TumorGenesis. “TumorGenesis is an interesting company. The whole purpose of it was to develop a lab media to replace rats and mice in the scientific industries and in the testing of tumors,” he stated in the interview. “They have developed the first one, which is ovarian cancer, and the results of this are that this media, which, as I said, replicates the body, fools the tumor into thinking it’s still in the body. Its reactions are very, very similar to what it would have done had it been in the body. Now, the next step is to get it positioned to manufacturers and getting the kits out so people can use it. That’s coming along handsomely. It’ll take a little time to get all this put in place, but the optimism is there, and the results are wonderful. We’re very excited.”
Founded in 2012, The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies.
Founded in 2012, The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies.
Cybin Corp. is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.
Cybin Corp. is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.
ISW Holdings (OTC: ISWH), based in Nevada, is a diversified portfolio company comprised of essential business lines that serve consumer product demands. Its expertise lies in strategic brand development, early growth facilitation, as well as brand identity through the company’s proprietary procurement process. Together with its partners, ISW Holdings seeks to provide a structure that meets large scalability demands as well as anticipated marketplace needs. It is able to meet these needs through a variety of strategic, innovative processes. ISWH is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which include conceptualization, go-to-market strategies, engineering, product integration, and distribution efficiency. The company has also partnered with a well-known software development and consulting company, Bengala Technologies LLC, which is developing significant enhancements in the supply chain management space; the partnership has a vitally needed patent pending.
ISW Holdings (OTC: ISWH), based in Nevada, is a diversified portfolio company comprised of essential business lines that serve consumer product demands. Its expertise lies in strategic brand development, early growth facilitation, as well as brand identity through the company’s proprietary procurement process. Together with its partners, ISW Holdings seeks to provide a structure that meets large scalability demands as well as anticipated marketplace needs. It is able to meet these needs through a variety of strategic, innovative processes. ISWH is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which include conceptualization, go-to-market strategies, engineering, product integration, and distribution efficiency. The company has also partnered with a well-known software development and consulting company, Bengala Technologies LLC, which is developing significant enhancements in the supply chain management space; the partnership has a vitally needed patent pending.
PowerBand Solutions (TSX.V: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA) is a fintech provider disrupting the automotive industry. PowerBand’s integrated, cloud-based transaction platform facilitates transactions amongst consumers, dealers, funders and manufacturers (“OEMs”). It enables them to buy, sell, trade, finance, and lease new and used, electric- and non-electric vehicles, on smart phones or any other online digital devices, from any location. PowerBand’s transaction platform – being trademarked under DRIVRZ – is being made available across North American and global markets.
National Storm Recovery (OTC: NSRI), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company and its Sustainable Green Team’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through the company’s tree services division and collection sites, and then, through the company’s processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients.
National Storm Recovery (OTC: NSRI), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company and its Sustainable Green Team’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through the company’s tree services division and collection sites, and then, through the company’s processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients.
The Movie Studio (OTC: MVES) operates as a vertically integrated motion-picture production and distribution company. The company acquires, develops, produces and distributes independent motion-picture content for worldwide consumption via theatrical release, video on demand, foreign sales and various media devices. MVES is disrupting traditional media-content delivery systems with its digital business model of motion picture distribution. The company was formerly known as Destination Television Inc. and changed its name to The Movie Studio Inc. in November 2012. The Movie Studio Inc. was founded in 1961 and is headquartered in Fort Lauderdale, Florida.
The Movie Studio (OTC: MVES) operates as a vertically integrated motion-picture production and distribution company. The company acquires, develops, produces and distributes independent motion-picture content for worldwide consumption via theatrical release, video on demand, foreign sales and various media devices. MVES is disrupting traditional media-content delivery systems with its digital business model of motion picture distribution. The company was formerly known as Destination Television Inc. and changed its name to The Movie Studio Inc. in November 2012. The Movie Studio Inc. was founded in 1961 and is headquartered in Fort Lauderdale, Florida.
Exro Technologies (CSE: XRO) (OTCQB: EXROF) is a Clean Tech company that has developed a new class of control technology for electric powertrains. Exro’s advanced motor control technology, its “Coil Driver,” expands the capabilities of electric motors and powertrains. The Coil Driver enables two separate torque profiles within a given motor. The first is calibrated for low speed and high torque, while the second provides expanded operation at high speed. The ability to change configuration allows efficiency optimization for each operating mode, resulting in overall reductions in energy consumption. The controller automatically and seamlessly selects the appropriate configuration in real-time so that torque demand and efficiency are optimized.
Exro Technologies (CSE: XRO) (OTCQB: EXROF) is a Clean Tech company that has developed a new class of control technology for electric powertrains. Exro’s advanced motor control technology, its “Coil Driver,” expands the capabilities of electric motors and powertrains. The Coil Driver enables two separate torque profiles within a given motor. The first is calibrated for low speed and high torque, while the second provides expanded operation at high speed. The ability to change configuration allows efficiency optimization for each operating mode, resulting in overall reductions in energy consumption. The controller automatically and seamlessly selects the appropriate configuration in real-time so that torque demand and efficiency are optimized.
Sigma Labs (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time.
Bullfrog Gold (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation that controls the commanding land and mineral positions in the Bullfrog Mine area. In this area, Barrick produced 2.3 million ounces of gold through conventional milling beginning in 1989 and ending in 1999.
Sigma Labs (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time.
Bullfrog Gold (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation that controls the commanding land and mineral positions in the Bullfrog Mine area. In this area, Barrick produced 2.3 million ounces of gold through conventional milling beginning in 1989 and ending in 1999.
Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S,-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the United States today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S., including several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol UUUU; the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol EFR.
Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S,-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the United States today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S., including several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol UUUU; the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol EFR.
National Storm Recovery (OTC: NSRI), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company and its Sustainable Green Team’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then through processing, recycling and using that tree debris as feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic-growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. NSRI serves governmental, residential and commercial customers.
National Storm Recovery (OTC: NSRI), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company and its Sustainable Green Team’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then through processing, recycling and using that tree debris as feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic-growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. NSRI serves governmental, residential and commercial customers.
Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other) that contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform Kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.
Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other) that contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform Kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.
Champignon Brands (CSE: SHRM) has positioned itself to rapidly become a global force as a vertically integrated producer of artisanal medicinal mushrooms and associated products. The Champignon team is focused on enhancing the health and wellness of millions of consumers who can benefit from its premium suite of organic, sustainable and non-GMO mushroom and mushroom-infused formulations.
Champignon Brands (CSE: SHRM) has positioned itself to rapidly become a global force as a vertically integrated producer of artisanal medicinal mushrooms and associated products. The Champignon team is focused on enhancing the health and wellness of millions of consumers who can benefit from its premium suite of organic, sustainable and non-GMO mushroom and mushroom-infused formulations.
Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canadian‐based exploration company focused on the acquisition and development of production grade cobalt and nickel deposits, key raw material inputs for the growing lithium‐ion battery industry.
Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canadian‐based exploration company focused on the acquisition and development of production grade cobalt and nickel deposits, key raw material inputs for the growing lithium‐ion battery industry.
SRAX (NASDAQ: SRAX) is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor-relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.
SRAX (NASDAQ: SRAX) is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor-relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.
Plus Products (CSE: PLUS) (OTCQX: PLPRF) is a hemp and cannabis food company focused on using nature to bring balance to consumers’ lives. PLUS’s mission is to make cannabis safe and approachable, beginning with high-quality products that deliver consistent consumer experiences. PLUS is headquartered in San Mateo, California, and has 80 employees. For more information, visit the company’s website at www.PlusProductsInc.com.
MCTC Holdings Inc. (MCTC), doing business as Cannabis Global Inc., is focused on delivering long-term shareholder growth and results. The company invests with confidence and determination to be the forefront of the cannabis and CBD revolution.
Sigma Labs (NASDAQ: SGLB) is an emerging provider of quality-assurance software to the commercial 3D-printing industry under the PrintRite3D brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection (“CAI”) solutions known as PrintRite3D for 3D, advanced-manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time.
Trxade Group (NASDAQ: MEDS) (OTCQB: TRXD) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals, accessories and services. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; the Trxade B2B trading platform with 11,000 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy capabilities including DelivMeds, as well as the newly acquired assets of Bonum Health.
No Borders (OTC: NBDR) is a multifaceted corporation specializing in the acquisition, creation and scaling of commercial and consumer products by utilizing cutting-edge technologies to reduce costs while increasing revenues and shareholder value through technological superiority across its portfolio of assets.
Predictive Oncology (NASDAQ: POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.
Wonderfilm (OTCQB: WDRFF) (TSX.V: WNDR) is a leading entertainment company with production offices in Los Angeles and corporate offices in Vancouver. The company’s core business is producing market-driven independent feature films and quality television series for multi-platform global exploitation. Wonderfilm is a producer and distributor only for the projects disclosed. The legal ownership of movie productions is held in a special purpose legal entity held at arm’s length to the company to facilitate for the qualification of various levels of domestic and foreign government tax credit incentives that are customary in the film and production business.
OriginClear (OTC: OCLN) addresses the self-reliant water revolution, deploying advanced technologies at the point of use with modular, prefabricated systems that create durable assets and water independence for industry, commerce and agriculture. From its Texas-based factory, OriginClear designs and prefabricates an entire line of plug-n-play containerized Modular Water Systems(TM) that enable water purification, recycling and wastewater management. The company manufactures and distributes these professional-grade, self-reliant units to commercial and industrial properties such as hotels and resorts, real estate housing developments, office buildings, military installations, schools, farms, food and beverage manufacturers, industrial warehouse, oil & gas producers, and medical and pharmaceutical facilities.
LiveWire Ergogenics (OTC: LVVV) specializes in identifying and monetizing current and future trends in the human and veterinarian health and wellness industry. The company is focused on acquiring, managing and licensing specialized “closed loop” turnkey cannabis real estate locations of fully compliant and permitted turnkey facilities to produce cannabis-based products and services in California and the state-wide distribution of these products. This includes verification of zero pesticide products for quality brands via its “7X Pure” Cannabis Verification System, and the development, licensing and distribution of legal, high-quality cannabinoid-based products and services. LiveWire Ergogenics does not sell or distribute products that are in violation of the United States Controlled Substance Act.
Organigram Holdings (TSX: OGI) (NASDAQ: OGI) is a Toronto Stock Exchange and NASDAQ Global Select-listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult-recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult-use recreational cannabis brands including the Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick, and the company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).
CloudCommerce (OTCQB: CLWD) is a leading provider of audience-driven, business-intelligence and digital-marketing solutions. The company’s flagship solution, SWARM, analyzes a robust mix of audience data to help businesses find who to talk to and what to say to when they motivate those businesses to take meaningful action. CloudCommerce does this by applying advanced data science, behavioral science, artificial intelligence and market-research techniques to discover, develop and create custom audiences for any business activity. With applications such as marketing, brand perception, customer-relationship management, human-resources management and operational logistics, SWARM delivers powerful, audience-driven business intelligence to convert opportunities into business success.
Xalles Holdings (OTC: XALL) is a holding company that focuses on direct investments in disruptive fintech companies. The company actively seeks acquisition targets in which it can invest and accelerate growth, targeting companies with solid management teams and business models, large total attainable markets (“TAM”), and lucrative exit opportunities. The company places emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which, over time, will allow for the capture of recurring revenue streams.
SRAX (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through the BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby offering everyone in the Internet ecosystem choice, transparency, and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.
Quest Patent Research (OTCQB: QPRC) operates as an intellectual-property, asset-management company delivering financial, strategic and legal resources for IP monetization. It partners with inventors, businesses, corporations and law firms to fully realize the value of IP assets through its suite of value-added services. Quest currently owns, controls or manages more than 115 patents across 11 intellectual property portfolios. Quest trades on the OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process.
ORHub Inc. (OTC: ORHB) is a growth-stage data analytics company on a mission to optimize the business of surgery through lean process improvement. As a Microsoft Silver Partner, ORHub leverages the Azure cloud to help customers unlock the power of data captured in the operating room by surfacing key business indicators into a curated set of dynamic dashboards.
Neutra (OTCQB: NTRR) is an early-stage research and development company committed to bringing modern, healthy-living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture — one where consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical submarkets is the new, thriving, hemp-based CBD market, in which the company intends to participate.
Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), headquartered in Xiamen, China, is a producer, developer and operator of augmented-reality, interactive entertainment games and toys, including interactive educational materials, mobile games and toys with mobile-game features.
Grapefruit Boulevard Investments, a wholly owned subsidiary of Imaging3 (OTCQB: IGNG), holds California permits and licenses to both manufacture and distribute cannabis products. Grapefruit’s cannabis and CBD extraction laboratory and distribution facilities are located in the industry recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Rd., approximately 10 miles north of downtown Palm Springs. Grapefruit obtained its California cannabis licenses in January of 2018 and commenced distribution of cannabis products thereafter. Grapefruit’s vision is to become a seed to sale, fully vertically integrated ethical and compliant cannabis and CBD product company. For more information, visit the company’s website at www.GrapefruitBlvd.com.
A TSX Venture Top 50 Company, Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of cellular communications systems for enterprise customers, specializing in connected vehicle products for professional fleets, marketed under the Uniden® Cellular brand. Since developing the world’s first 3G connected vehicle device, Siyata has been a pioneer in the industry, launching the world’s first 4G LTE all-in-one fleet communications device in 2017. Incorporating voice, push-to-talk over cellular, data, and fleet management solutions into a single device, the company aims to become the connected vehicle communications device of choice for commercial vehicles and fleets around the world. Siyata also offers rugged phones for industrial users and signal boosters for homes, buildings, and fleets with poor cell coverage. Siyata’s customers include cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia, and the Middle East.
VPR Brands LP (OTC: VPRB) is a technology company whose assets include issued U.S. and Chinese patents for atomization-related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The company is also engaged in product development for the vapor or vaping market including e-liquids. Vaporizers and electronic cigarettes (also known as e-cigarettes) are devices that deliver nicotine and/or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products.
Golden Developing Solutions (OTC: DVLP) is developing an online retail business for cannabidiol (CBD), hemp oil and health/wellness-related products. The company is also developing a high-capacity, high-quality CBD extraction and production facility. In addition, through wholesale and distribution channels, the company offers a broad range of high-quality, price-competitive products, including traditional vitamins; supplements; and CBD-based tinctures, vapes and soft gels, among other products. Merchandise also includes hemp and CBD-related products and additional products focusing on health and lifestyle.
Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.
ORHub (OTC: ORHB) is a growth stage data analytics company on a mission to optimize the business of surgery through lean process improvement. As a Microsoft Silver Partner, ORHub leverages the Azure cloud to help customers unlock the power in their data captured in the OR. Surgical Spotlight(R) helps providers harness that data, identify millions of dollars in opportunities, and get leaders back to their primary focus: improving care, increasing patient access and reducing costs. A first-of-kind team building tool brings all stakeholders together with regular and accessible information. ORHub specializes in business intelligence for the operating room, built by professionals from the operating room.
MustGrow Biologics Corp. (CSE: MGRO) is an agricultural biotech company focused on developing and commercializing its patented natural biologic product that acts as a pesticide, fungicide nematicide and fertilizer. Targeting the fruit, vegetable, turf, ornamentals and cannabis industries, MustGrow has designed a United States EPA-approved organic solution that uses the mustard seed’s natural defense mechanisms to protect plants from pests and diseases. Approximately $9 million has previously been spent on 110 independent tests, validating MustGrow’s remarkably safe and effective granular product. MustGrow’s granular product is EPA-approved across all key U.S. states as a fertilizer and pesticide (currently limited to fertilizer in California) and is designated by Health Canada’s PMRA (Pest Management Regulatory Agency) as a fruit, vegetable, turf and ornamental biopesticide and biofertilizer. In cannabis, MustGrow is currently developing reliable, safe and biological solutions that adhere to Health Canada’s strict regulations. MustGrow is positioning its signature product as an effective pre-plant soil treatment, reducing the chance for any added soil to a greenhouse to bring in pests or diseases. MustGrow expects its biopesticide and biofertilizer will help licensed cannabis producers control the same conditions addressed in fruit and vegetable crops.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
Hemptown USA, headquartered in Central Point, Oregon, is a proven grower of full-spectrum, feminized hemp grown using premium-seed genetics that contain less than 0.3% THC and exceptionally high cannabinoid (CBD) content of up to 20%. The company’s soil-to-oil methodology combines seasoned professionals working in handpicked agricultural microclimates located in Oregon’s famed Emerald Triangle and in Kentucky and Colorado.
Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) is a Vancouver-based company developing and designing brands that focus on plant-based health and wellness products. All of the company’s brands work in synergy, toward becoming a global wellness leader.
Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (Frankfurt: O3X4) intends to provide debt and equity funding in the middle to late stages of a target company’s development or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related and healthcare-related companies.
Genprex (NASDAQ: GNPX) is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer. Immunotherapy has come to the forefront in the fight against cancer, harnessing the body’s own immune system in recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a potent approach with the potential to prevent cancer recurrence.
The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF) is a publicly traded, premium global organic cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. The company grows high-quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned global capacity of 219,000 kgs. and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.
Black Iron (TSX: BKI) (OTC: BKIRF) (GR: BIN) is an iron ore exploration and development company, advancing its 100 percent owned Shymanivske project located in Kryviy Rih, Ukraine. The Shymanivske project contains a NI 43-101 compliant resource estimated to be 646 Mt Measured and Indicated mineral resources, consisting of 355 Mt Measured mineral resources grading 31.6 percent total iron and 18.8 percent magnetic iron, and Indicated mineral resources of 290 Mt grading 31.1 percent total iron and 17.9 percent magnetic iron, using a cut-off grade of 10 percent magnetic iron. Additionally, the Shymanivske project contains 188 Mt of Inferred mineral resources grading 30.1 percent total iron and 18.4 percent magnetic iron. Full mineral resource details can be found in the NI 43-101 compliant technical report entitled “Preliminary Economic Assessment of the Re-scoped Shymanivske Iron Ore Deposit” effective November 21, 2017, under the company’s profile on SEDAR. The Shymanivske project is surrounded by five other operating mines, including ArcelorMittal’s iron ore complex.
Kontrol Energy Corp. (CSE: KNR) (FSE: 1K8) is a leader in the energy efficiency sector through IOT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to its customers designed to reduce their overall cost of energy while providing a corresponding reduction in Greenhouse Gas (GHG) emissions.
Icon Exploration Inc. (TSX.V: IEX.H) is a publicly traded company on the NEX Exchange (TSXV: IEX.H). The company’s primary objective is to create a well-diversified company that will produce long-term returns for its shareholders and investors. Icon’s current focus is on assessing potential acquisition targets in the cannabis industry.
Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G) core mission is to become the leading supplier to the cannabis beverage and edibles market. The company’s Toronto based, ACMPR licensed facility was built to cultivate pharmaceutical grade cannabis to supply a technological breakthrough in producing and formulating the first natural, truly water-soluble cannabis solution. The company’s water-soluble ingredients and our bio-natural oils will deliver revolutionary brands to international markets that are clamoring for well-defined commercial products. Sproutly’s business focus is to execute on partnerships with local and globally established consumer brands to leverage their existing customer bases, further expand brand loyalty, assist with marketing, and support distribution networks to deliver this scientific breakthrough with speed and efficiency worldwide.
The Aziza Project has a bold vision: to light up Africa, bringing electricity to the 630 million Africans who currently have no access to the grid, and in the process, to deliver excellent returns to investors. How will this be achieved? The Aziza Project selects oil and gas related young businesses that have the potential to create intergenerational wealth for token holders, shareholders, communities and entrepreneurs.
Redfund Capital (CSE: LOAN) (Frankfurt: O3X4) (OTC: PNNRF) intends to provide debt and equity funding in the mid-to-late stages of a target company’s development or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related and healthcare-related companies.
Sharing Services Global Corporation (SHRG) is a diversified holding company specializing in the direct selling industry. SHRV owns, operates, or controls an interest in a variety of companies that either sell products to the consumer directly through independent representatives or offers services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits.
Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that also offers e-commerce and the power of social selling. Assembling a virtual Main Street of products and services under one corporate entity, Youngevity offers proven products from the six top-selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. The company was formed during the summer 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company (now part of the company’s food and beverage division). The resulting company became Youngevity International, Inc. in July 2013.
The Flowr Corporation (CVE:FLWR) (OTCMKTS:FLWPF), through its subsidiaries, is a vertically-integrated Canadian cannabis company focused on the natural science of cannabis. With head offices in Markham, ON and production in Kelowna, B.C., Flowr builds and operates large-scale, GMP compliant cultivation facilities utilizing their own patented growing systems. Flowr’s investment in research and development ensures that its master growers are able to supply patients with consistent, high-quality medicinal cannabis. With a sense of craftsmanship and a spirit of innovation, Flowr is also well positioned with a line of premium quality cannabis products for the upcoming adult-use market.
The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) is a research & development company licensed under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to cultivate medical cannabis. The Company carries out its principal activities producing cannabis from its facilities in Ancaster, Ont., pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations. The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a funded capacity of 170,000 kg and is building 1,382,000 sq. ft. of cultivation facilities in Ontario, Quebec and Jamaica. The Company has developed a strategic partnership with Aurora Cannabis Inc. (TSX: ACB) whereby Aurora has invested approximately C$78.1 million for an approximate 17.5% stake in TGOD. In addition, the Company has raised approximately C$350 million and has over 20,000 shareholders. TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.
Accelerated Technologies Holding Corp. (OTC: ATHC) is a full-service end-to-end business solution and technology company that specializes in cloud-based disruptive technologies. The Company provides consulting and enterprise-level technology services and is developing its own disruptive technology products in the sectors of artificial social realities, short-term alternative funding platforms, electronic payment solutions, and blockchain technologies focused on social engagement, sports, entertainment and content creation. ATHC and its economies of scale enable the Company to develop technology at reasonable costs while leveraging expertise and contacts for effective execution. ATHC’s investment domain and expertise lies in consumer Internet, cloud computing and software-as-a-service (SaaS), mobile software and services, software-powered consumer electronics, infrastructure and applications software, networking, storage, databases and other backend systems.
Auscrete Corp. (ASCK) is a building materials manufacturing company and constructor of “GREEN” energy efficient housing and commercial structures built from Auscrete developed lightweight hybrid concrete/insulation wall and roof panels. Structures built of this medium have very low maintenance needs and, being concrete, are highly resistant to insects and mold. They have considerable mass and are highly resistant to hurricane forces and earth tremors. They will not catch fire and burn. Auscrete is planning to establish their Flagship Facility in Goldendale, WA.
Founded in 2007, WhereverTV Broadcasting Corp. (TVTV) is the next generation subscription television service providing consumers with live-streaming, genre-specific, and in-language viewing choices from around the world, delivered to anywhere in the world, and through any internet enabled device. WhereverTV provides an economically beneficial and completely versatile alternative to traditional cable and satellite services, with the added benefits of personalization and portability. Also known as Internet TV, WhereverTV delivers content, shows and events to Smart TVs and digital media receivers including: iPhone, iPad, Android Smartphone and Tablet PCs. The WhereverTV patented IPG platform enables subscribers to access licensed content from content providers from around the world. The customer viewing experiences are based on customer location (geo-targeting) and content/digital-rights management contracts. Apps are presently available for free with in app purchases for Apple TV, iOS phones and iPads in the Apple Store. WhereverTV is currently available for Android Phones and tablets in the Google Play Store. WhereverTV is also available on Amazon Fire TV Stick. Samsung & LG Smart TV’s, Roku and DVR functionality to record shows and view later are presently in the works.
GTX Corp (GTXO) is a pioneer in smart, mobile and wearable GPS tracking and recovery location-based products, supported through a proprietary IoT enterprise monitoring platform. GTX offers a global end-to-end solution of hardware, software and connectivity. GTX Corp develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications. GTX Corp utilizes the latest in miniaturized, low power consumption GPS, cellular, RF and BLE technology, enabling subscribers to track in real time the whereabouts of people or high-value assets through a complete end to end — customizable transceiver module, wireless connectivity gateway, smart phone apps, middleware, and IoT portal. Headquartered in Los Angeles, California, GTX is known for its game-changing and award-winning patented GPS SmartSole® — think Dr. Scholl’s meets LoJack, the world’s first invisible, wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism and traumatic brain injury. GTX Corp’s business model is built around technology innovation and holds over 85 patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing customers in over 35 countries and is a U.S. Military Government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, NGOs, private companies, public and private senior care homes, and consumers.
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S., it aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, the company’s cloud based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™. In 2017, Net Element was recognized by South Florida Business Journal’s as one of 2016’s fastest growing technology companies.
Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technology company engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry. Foresight’s vision systems are based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company, through its wholly owned subsidiary Foresight Automotive Ltd., develops advanced systems for accident prevention which are designed to provide real-time information about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts. The company’s systems are targeting the Advanced Driver Assistance Systems (ADAS), semi-autonomous and autonomous vehicle markets. The company estimates that its systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform and advanced technology.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website.
BLOCKStrain Technology Corp. (TSX-V: DNAX), headquartered in Vancouver, Canada, is an integrated blockchain platform that registers and tracks cannabis intellectual property (“IP”) from genome to sale. BLOCKStrain’s proprietary, immutable, cryptographically secure blockchain technology establishes a global single source of truth for cannabis strains and their ownership. By offering a secure API network, BLOCKStrain makes it easy for cannabis testing providers, grow facilities, app and software developers, research groups and major supply chain platforms to build cannabis-centric applications that will help fuel technology and innovation for this rapidly growing sector.
First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) aims to create the largest pure-play cobalt exploration and development company in the world. First Cobalt controls over 10,000 hectares of prospective land covering over 50 historic mines as well as mineral processing facilities in the Cobalt Camp in Ontario, Canada. The First Cobalt Refinery is the only permitted facility in North America capable of producing cobalt battery materials. First Cobalt seeks to build shareholder value through new discovery, mineral processing and growth opportunities, with a focus on North America.
Epazz, Inc. (OTC: EPAZ) is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company’s strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.
First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, seeks to create the world’s largest pure-play cobalt exploration and development company. The company’s current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.
Teewinot Life Sciences is an international biopharmaceutical company employing its patent-protected CannSynthesis® technology to biosynthesize cannabinoids for the large-scale manufacture of pharmaceutically pure cannabinoids including the varin series of compounds, which are only found in relatively small quantities in the cannabis plant. Teewinot’s focus is on the biosynthetic production of pure, naturally-occurring cannabinoids, cannabinoid prodrugs and analog compounds by utilizing proprietary biocatalysis and synthetic biology for clinical development of FDA-approved pharmaceuticals. To date, Teewinot researchers have synthesized over 18 different naturally occurring cannabinoids in pharmaceutically pure form. The company employs its proprietary, disruptive technology to develop therapeutics for diseases identified as viable cannabinoid targets such as pain management, opioid addiction, oncology, psychiatric and central nervous system disorders, inflammation, and other drug development indications. Headquartered in Tampa, Florida, Teewinot is a global leader in the manufacturing and delivery of safe and standardized products containing cannabinoids, cannabinoid prodrugs, and cannabinoid analogs for diverse consumer markets. The company’s wholly owned subsidiaries in Ireland and Canada, along with collaborations formed with key research institutions, consumer product companies, manufacturers, and local communities, combine cutting-edge scientific research on cannabinoids with an aggressive intellectual property portfolio to create new and improved patient therapies.
SinglePoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.
Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.